CD8A and head and neck squamous cell carcinoma: Thus, we performed the CheckRad‐CD8 investigator‐initiated phase II clinical trial (NCT03426657), where a single cycle of iCIT (combination of cisplatin/docetaxel with programmed cell death ligand 1 [PD‐L1] and cytotoxic T lymphocyte‐associated antigen 4 [CTLA‐4] inhibitors durvalumab plus tremelimumab) led to pathologically confirmed complete response rates (pCR) of 48% and improved progression‐free survival (PFS) in patients with locally advanced HNSCC [13, 14].